INC Research is the latest among Big Pharma's biggest contractors to pull off an IPO, raising $150 million and joining its largest rivals on Wall Street.
INC Research has spelled out its IPO plans, looking to raise $150 million through the sale of 8.1 million shares at $17 to $20 a share.
Provectus Biopharmaceuticals, a biotech that has been stung by regulatory setbacks, has recruited INC Research to audit its data on two drug candidates, tasking the CRO with poring over its documents as it moves into late-stage development.
Following a trend among the companies that do Big Pharma's heavy lifting, global CRO INC Research has filed to go public, looking to raise $150 million.
Global CRO INC Research has teamed up with a trade group of clinical research sites, lending its expertise in an effort to better integrate sponsors, CROs and investigators in the R&D process.
INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.
As more and more eyes turn toward Japan for clinical trials, INC Research is setting up two outposts in the country, building off years of local partnerships and going it alone in the growing market.
BOSTON-- Walking through the annual Drug Information Association meeting, you can't miss the signs of consolidation, from the HCR tacked onto Synteract's logo to the buzz around PRA's corner of the conference when attendees found out it was soon to change hands for $1.3 billion. Read the feature >>
Behind the huge and scary numbers that accompany the costs of drug development, there are various holes and dysfunctional practices in the process of bringing a new drug to market.
Fresh off raising $12 million in Series B financing, goBalto has lured a major CRO with its cloud-based clinical development platform, signing a deal with INC Research.